Stem Pharma Collaborates with Verge Genomics to Treat Parkinson's

Stem Pharm Inc., a drug discovery platform company that leverages 3D neuro-immune organoids , and Verge Genomics, a biotechnology company that transforms drug discovery by leveraging artificial intelligence (AI) and patient tissue data, announced a collaboration to develop a disease model to validate novel targets identified by Verge Genomics for Parkinson's disease. Parkinson's disease is a neurological ailment that affects millions of individuals worldwide. The disease's intricacy and diversity have provided considerable obstacles in the development of effective medicines. Verge Genomics and Stem Pharm have joined forces to use cutting-edge human-first technology and expertise, recognizing the critical need for innovation.

The partnership will centre on leveraging the power of neural organoids, which are three-dimensional models of human neural tissue produced from stem cells. Neural organoids provide a unique platform for studying the complexities of the disease and simulating its course in the laboratory. The businesses want to obtain crucial insights into the disease's fundamental mechanisms and evaluate possible therapeutic targets by developing a Parkinson's disease model utilizing brain organoids as per Pharmabiz. "We are ecstatic to be collaborating with Verge Genomics to apply our neuro-immune organoid platform to Parkinson's disease," stated Stem Pharm CEO Steven Visuri. "Verge's all-in-human approach to drug discovery aligns perfectly with our ideology, and we hope to establish a cutting-edge Parkinson's disease model by combining our strengths and resources." This collaboration is an important step forward in our combined effort to find revolutionary solutions for those suffering from this devastating disease."